., Sebastine and Fathima, Mohamed Zerein (2024) Nanosuspensions in Breast Cancer Therapy: A Comprehensive Overview. INTERNATIONAL JOURNAL OF DRUG DELIVERY TECHNOLOGY, 14 (02). pp. 1090-1098. ISSN 0975-4415
![[thumbnail of IJDDT,Vol14,Issue2,Article73.pdf]](https://ir.vistas.ac.in/style/images/fileicons/archive.png)
IJDDT,Vol14,Issue2,Article73.pdf
Download (418kB)
Abstract
Nanosuspensions in Breast Cancer Therapy: A Comprehensive Overview Sebastine . Mohamed Zerein Fathima
Nanosuspensions offer a promising avenue for enhancing breast cancer treatment through improved drug delivery, solubility, and targeting. These colloidal dispersions contain submicron drug particles, significantly increasing surface area and enhancing drug solubility and dissolution rates. This improvement can lead to increased drug bioavailability, enabling lower doses and reduced side effects. It is also possible to engineer nanosuspensions so that they are controlled-release drugs, providing sustained therapeutic levels at the tumor site. Nanosuspensions facilitate targeted drug delivery, which is one of their key advantages. In order to minimize systemic toxicity, nanosuspensions contain targeting ligands or antibodies that adhere to the surface of nanoparticles in order to deliver drugs specifically to breast cancer cells. The nanosuspension platform also allows a combination therapy approach to be used, allowing multiple drugs to be delivered simultaneously in order to achieve synergistic effects and combat drug resistance. Nanosuspension treatments can be beneficial both therapeutically and for imaging and diagnostic purposes. Using nanoparticles labeled with imaging agents, it is possible to visualize tumors and monitor treatment responses. Nanosuspensions may reduce side effects associated with traditional chemotherapy by improving drug targeting and reducing systemic exposure. A nanosuspension represents a promising treatment option for breast cancer. Nanosuspensions must be fully exploited for their full potential to improve outcomes and quality of life for patients.
06 24 2024 1090 1098 http://creativecommons.org/licenses/by-nc-nd/4.0 10.25258/ijddt.14.2.73 https://impactfactor.org/PDF/IJDDT/14/IJDDT,Vol14,Issue2,Article73.pdf
Item Type: | Article |
---|---|
Subjects: | Pharmaceutics > Pharmacognosy |
Divisions: | Pharmaceutics |
Depositing User: | Mr IR Admin |
Date Deposited: | 05 Oct 2024 06:37 |
Last Modified: | 05 Oct 2024 06:37 |
URI: | https://ir.vistas.ac.in/id/eprint/8686 |